Breaking News

BASF, Bend Research in Solubility Pact

February 21, 2013

Aims to develop excipients to enhance solubility, bioavailability

BASF and Bend Research have signed an agreement to evaluate and develop excipients to enhance the solubility and bioavailability of poorly soluble drugs. The collaboration aims to meet increasing challenges of poorly soluble APIs (BCS Class II and IV compounds). The initial focus will be on optimizing new vinylpyrrolidone based copolymers being developed for the solubilization of poorly soluble APIs.
BASF will provide its expertise in ingredient formulation and material science and its excipient products, while Bend Research with utilize its formulation development technology in the field of spray drying and hot-melt extrusion.
"We are excited about the opportunities this collaboration brings to us and our customers," said Rod Ray, chief executive officer of Bend Research. "It offers early access to a different set of chemistries and allows us to develop and test customer formulations based on new polymers. BASF has an impressive track record developing and launching novel excipients. This deal complements our recently announced collaboration on cellulosics, because it gives us access to completely different chemistries."
"We are glad to bring our in-depth knowledge of polymeric excipients into this collaboration to jointly extend the current toolbox already comprising innovations like Soluplus,” said Ralf Fink, vice president global marketing at BASF Pharma Ingredients & Services business unit. “Coupled with Bend Research’s outstanding strengths in formulation development, including spray-drying and hot-melt extrusion, we are in a unique position to address urgent solubility challenges. With this partnership, we help our customers with the development of drugs with poor bioavailability."

Related Contract Manufacturing:

Related Packaging:

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO